Moxley T E, Royer G L, Hearron M S, Donovan J F, Levi L
J Am Geriatr Soc. 1975 Aug;23(8):343-9. doi: 10.1111/j.1532-5415.1975.tb00324.x.
In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis. Of the 159 patients from the 17 contributing clinics, 144 completed the four weeks of therapy. More than 60 per cent of them reported improvement in exercise-related pain by week 4, and there was no significant difference between treatment groups. The patients' and the physicians' evaluations of the total state of disease, as well as range-of-motion and functional tests, demonstrated similar degrees of improvement in both treatment groups. The incidence of side effects was within acceptable limits, and the frequency distribution was similar in both groups. Of the 70 reported side effects, 29 were considered by the investigator (blind trial) to be drug-related-11 in association with ibuprofen and 18 with phenylbutazone-alka. Hematologic and blood chemical studies, as well as urine and stool examinations, yielded normal results with the exception of a reduced mean value for serum uric acid and a slightly elevated mean value for SGPT in the phenylbutazone-alka group.
在一项双盲多诊所试验中，将一种新型非甾体抗炎药（布洛芬）与一种已确立的治疗药物（保泰松 - 阿尔卡）用于骨关节炎治疗进行了比较。来自17个参与诊所的159名患者中，有144名完成了为期四周的治疗。到第4周时，超过60%的患者报告与运动相关的疼痛有所改善，且治疗组之间无显著差异。患者和医生对疾病总体状况以及活动范围和功能测试的评估表明，两个治疗组的改善程度相似。副作用发生率在可接受范围内，两组的频率分布相似。在报告的70例副作用中，研究者（盲法试验）认为29例与药物相关——11例与布洛芬有关，18例与保泰松 - 阿尔卡有关。血液学和血液化学研究以及尿液和粪便检查结果均正常，但保泰松 - 阿尔卡组血清尿酸平均值降低，谷丙转氨酶平均值略有升高。
